Trial · NCT02222545
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA | OMS721 Low Dose | 0 | Participants | ||
| Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA | OMS721 Medium Dose | 0 | Participants | ||
| Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA | OMS721 High Dose | 27 | Participants | ||
| Number of Participants With HSCT-TMA Who Respond to OMS721 | OMS721 Low Dose | 0 | Participants | ||
| Number of Participants With HSCT-TMA Who Respond to OMS721 | OMS721 Medium Dose | 0 | Participants | ||
| Number of Participants With HSCT-TMA Who Respond to OMS721 | OMS721 High Dose | 17 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: 100-day Survival | OMS721 Low Dose | 0 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: 100-day Survival | OMS721 Medium Dose | 0 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: 100-day Survival | OMS721 High Dose | 19 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: Overall Survival | OMS721 High Dose | 274 | 95% Confidence Interval 103 to NA | days | |
| Participants With HSCT-TMA Treated With OMS721: Duration of Response | OMS721 High Dose | 561 | 95% Confidence Interval 185 to 757 | Days | |
| Participants With HSCT-TMA Treated With OMS721: Freedom From Platelet Transfusion | OMS721 High Dose | 8 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: Freedom From Red Blood Cell (RBC) Transfusion | OMS721 High Dose | 11 | Participants | ||
| Participants With HSCT-TMA Treated With OMS721: Change From Baseline in Platelet Count | OMS721 High Dose | 29.5 | 95% Confidence Interval 13.5 to 45.6 | 10^9 cells per liter | |
| Participants With HSCT-TMA: Pharmacokinetics (PK) of Multiple-dose Administration of OMS721 | HSCT-TMA | 0.1422 | Standard Deviation 0.0918 | L/H | |
| Participants With HSCT-TMA (ADA) | OMS721-TMA-001 HSCT-TMA High Dose | 3 | Participants | ||
| Participants With HSCT-TMA (ADA) | OMS721-TMA -001 TTP Medium Dose | 0 | Participants | ||
| Participants With HSCT-TMA (ADA) | OMS721-TMA -001 TTP High Dose | 1 | Participants | ||
| Participants With HSCT-TMA (ADA) | OMS721-TMA-001 aHUS Low Dose | 1 | Participants | ||
| Participants With HSCT-TMA (ADA) | OMS721-TMA-001 aHUS Medium Dose | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02222545/results